PARIS, March 23, 2021 /PRNewswire/ — Unither Pharmaceuticals, the Blow-Fill-Seal (BFS) worldwide leader, provides diagnostic companies with capacity solutions and innovative technologies for their testing kits (Covid, Flu, etc.).
With more than 10 million unit-doses manufactured each month for Covid testing kits, the French CDMO answers to current challenges based on its sterile unit doses development and manufacturing expertise.
The use of Blow-Fill-Seal technology, enables RNase-free single doses, that can also be sterile if necessary.
Through its 5 BFS plants on three continents (in France, the United States and China) and a R&D development center, Unither is able to manage the full development of a diluent or reagent from formulation to production.
About Unither Pharmaceuticals
Founded in Amiens, France, in 1993, Unither Pharmaceuticals has become a worldwide leader in drug manufacturing for generic pharmaceutical companies including but not limited to, eye drops and respiratory unit doses, saline solutions, and stick-packs.
Unither Pharmaceuticals has 7 manufacturing sites and 1 R&D center located in France, the United States, China and Brazil. These sites generated a revenue of €330 million in 2020 with a headcount exceeding 1.600 employees.
Website : www.unither-pharma.com
The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.